Kyowa Kirin Co., Ltd.

This study monitors how well Poteligeo works and what side effects occur when used in routine medical practice for adults with mycosis fungoides or Sézary syndrome—rare types of skin cancer. Researchers will track 15 Korean patients who have tried at least one other treatment bef…

This is the first study in humans testing a new drug called KK2260 for people with advanced or spreading solid tumors. Researchers will first determine the safest dose and then test it in patients with specific cancers like esophageal and head/neck cancer. The main goals are to c…

This early-stage study is testing the safety of a new drug called KK3910 for high blood pressure. Researchers will give single doses to healthy volunteers and multiple doses to people with hypertension to check for side effects. The study will also measure how the drug moves thro…

This is the first study in people for a new drug called KK2269. It aims to find a safe dose and see how well the body tolerates it. The study will test KK2269 alone in people with various advanced solid tumors, and also test it combined with a standard chemotherapy drug (docetaxe…

This is the first time a new drug called KK2845 is being tested in people. The study aims to find a safe and tolerable dose for adults with acute myeloid leukemia (AML) that has returned after treatment or has not responded to standard therapies. Researchers will monitor patients…

This is the first study in people to test an experimental drug called KK8123, given as an injection under the skin. It aims to find a safe and tolerable dose for adults with X-linked hypophosphatemia (XLH), a rare genetic disorder that causes weak bones and low phosphate levels. …